Crystal Pharmatech Co., Ltd.

Crystal Pharmaceutical (suzhou) Co., Ltd.

Receptos, Inc.

Suzhou Pengxu Pharmatech Co., Ltd.

Glaxosmithkline Intellectual Property (no.2) Limited

Anacor Pharmaceuticals, Inc.

Rogers Corporation

Crystal Pharmatech Inc.

Crystal Pharmaceuticals (suzhou) Co., Ltd.

Glaxosmithkline Intellectual Property Limited

Crystal Pharmaceutical Co., Ltd.

Xiaoyu Zhang

Yanfeng Zhang

Minhua Chen

Chaohui Yang

Xiaoting Zhai

Kaiqiang Yan

Kai Liu

Po Zou

Xiaojuan Diao

Nan Xia

Jinqiu Wang

Jiaoyang Li

Fei Lu

Peng Wang

Pixu Li

Chunxiang Huang

Qiyue Liu

Liang Zhang

Li Zhang

Yajie Chen

Shu Yu

Hui Gao

Yuhao Chen

Cunbo Yang

Heng Ge

Yuanyuan Xing

Lie Chen

The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Crystalline forms of ozanimod and processes for preparation thereof

The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

Crystal forms of crisaborole in free form and preparation method and use thereof

The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development. 

Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof

A multilayer film includes a substrate; a first magnetic layer disposed on the substrate and a second magnetic layer disposed on the first magnetic layer. The first magnetic layer includes FeNBM, wherein M is Si, Ta, Zr, Ti, Co, or a combination thereof. The second magnetic layer includes FeNor FeNTa. The multilayer magnetic film has, over a frequency range of 50 MHz to 10 GHz, a magnetic permeability of greater than or equal to 1800 over a selected frequency band in the frequency range; a magnetic loss tangent of less than or equal to 0.3 over a selected frequency band in the frequency range; and a cutoff frequency of greater than or equal to 1 GHz, or greater than or equal to 2 GHz.

High frequency magnetic films, method of manufacture, and uses thereof

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof. 

Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof

The present disclosure relates to a crystalline form of compound I and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing serotonin, norepinephrine and dopamine triple reuptake inhibitors drugs, and/or use of the crystalline form for preparing drugs treating nervous system disorders. The crystalline form of the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development. 

Crystalline form of EB-1020, processes for preparation and use thereof

The present disclosure relates to novel crystalline forms of compound (I) and processes for preparation and use thereof. Crystalline forms CS3, CS2, CS5 and CS8 of compound (I) of the present disclosure have advantages in at least one aspect of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification effect, flowability, adhesiveness, stability in drug product, in vitro and in vivo dissolution, etc., which provides new and better choices for preparation of drug product containing compound (I) and has significant values for future drug development. 

Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof

The present disclosure relates to crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art and have significant values for future drug optimization and development. 

Crystal form of Baricitinib and preparation method thereof

The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development. 

The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof. 

Crystal form of ozanimod hydrochloride and processes for preparation therefor

The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (I)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development. 

Crystal forms of an androgen receptor antagonist, preparation method and use thereof

The present disclosure relates to novel crystalline forms of VX-787, processes for preparation thereof and use thereof. VX-787 is a viral-protein inhibitor drug. The present disclosure provides crystalline form CS1, crystalline form CS2, crystalline form CS3, and crystalline form CS4 of compound (I) hydrochloride. The present disclosure also provides crystalline form CS3 and crystalline form CS9 of compound (I).free form. 

Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof

Growing community of inventors

Suzhou, China

Xiaoyu Zhang